Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.
Press releases published on July 7, 2025
Medicines for Poland Announces: Without pharmaceutical factories Europe will lose any war
GlobeNewswire
·
July 7, 2025
BRUSSELS, July 07, 2025 (GLOBE NEWSWIRE) -- The need to establish a fund under the EU budget to support the production of critical medicines in Europe is a conclusion drawn from an analysis of the impact of the war on the availability of medicines in …
Textile Recycling Market Projected to Reach $7.26 Billion by 2032, Growing at a 4.9% CAGR Amid Rising Sustainability Initiatives | AnalystView Market Insights
GlobeNewswire
·
July 7, 2025
San Francisco, USA, July 07, 2025 (GLOBE NEWSWIRE) -- The global Textile Recycling Market is experiencing a steady transformation as environmental concerns, sustainability goals, and circular economy initiatives reshape industry priorities. Valued at USD 7 …
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire
·
July 7, 2025
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W …
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
GlobeNewswire
·
July 7, 2025
LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro …
Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025
GlobeNewswire
·
July 7, 2025
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, double-blind, placebo-controlled Phase 2b study of sorafenib ( …
FuelCell Energy CEO Jason Few Applauds “One Big Beautiful Bill Act” as Catalyst for U.S. Clean Energy Leadership
GlobeNewswire
·
July 7, 2025
DANBURY, Conn., July 07, 2025 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) President and CEO Jason Few has issued a statement praising the “One Big Beautiful Bill Act” (OBBBA) for its direct support of the fuel cell industry and its role in …
CryptoMiningFirm 2025 Trusted Free Bitcoin Cloud Mining Platform Launches New Mobile App
GlobeNewswire
·
July 7, 2025
San Francisco, California, July 07, 2025 (GLOBE NEWSWIRE) -- In the cryptocurrency space, few platforms have as high a revenue stream as CryptoMiningFirm - and CryptoMiningFirm is one of them. It provides a worry-free, secure, and environmentally friendly …
Bluewave Nexor: This Bluewave Nexor App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
GlobeNewswire
·
July 7, 2025
New York City, NY, July 07, 2025 (GLOBE NEWSWIRE) -- As digital transformation continues to redefine global markets, Bluewave Nexor has emerged as one of the most talked-about innovations in AI-driven trading. At a time when market unpredictability and …
BTC Miner Announces Million-Dollar Cloud Mining Opportunity After Bitcoin’s Surge
GlobeNewswire
·
July 7, 2025
New York City, NY, July 07, 2025 (GLOBE NEWSWIRE) -- You may have missed the Bitcoin surge, but the opportunity isn’t over. BTC Miner offers you a low-barrier, high-reward investment opportunity where you can easily participate in Bitcoin, Ethereum, and …
Redevances OR annonce les livraisons préliminaires d’onces d’équivalent d’or pour le deuxième trimestre de 2025 et des produits trimestriels et une marge monétaire records
GlobeNewswire
·
July 7, 2025
MONTRÉAL, 07 juill. 2025 (GLOBE NEWSWIRE) -- Redevances OR Inc. (la « Société » ou « Redevances OR ») (TSX et NYSE : OR) a le plaisir de fournir une mise à jour sur ses livraisons, ses produits et sa marge monétaire préliminaires pour le deuxième trimestre …
OR Royalties Announces Preliminary Q2 2025 GEO Deliveries Along with Record Quarterly Revenue & Cash Margin
GlobeNewswire
·
July 7, 2025
MONTRÉAL, July 07, 2025 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX …
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
GlobeNewswire
·
July 7, 2025
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new …
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
GlobeNewswire
·
July 7, 2025
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from …
CORRECTION – Dr. Anosh Ahmed Announces Major Expansion of COVID Testing Contracts Across U.S. and International Markets
GlobeNewswire
·
July 7, 2025
CHICAGO, July 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on June 25, 2025 11:00 ET by Dr. Anosh Ahmed, please note that the media contact should be Dr. Anosh Ahmed, +1 (346) 768 7004, Info@pfoaa.com. The corrected release …
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
GlobeNewswire
·
July 7, 2025
Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today announced the last …
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
GlobeNewswire
·
July 7, 2025
Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision …
OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
GlobeNewswire
·
July 7, 2025
Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that …
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewswire
·
July 7, 2025
WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Shoals Technologies Group, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call
GlobeNewswire
·
July 7, 2025
PORTLAND, Tenn., July 07, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its second quarter 2025 results before market open on Tuesday, August 5, 2025, to be followed by …
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
GlobeNewswire
·
July 7, 2025
LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh …